A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors
Review of Second-Line Chemotherapy for Disseminated Germ Cell Tumors
MH Voss, DR Feldman, GJ Bosl, RJ Motzer
Yes
20110501
2011 Jun 1
Hematol Oncol Clin North Am
A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors
Hematol Oncol Clin North Am. 2011 Jun 1;25(3):557-576, MH Voss, DR Feldman, GJ Bosl, RJ Motzer
Abstract
Abstract
Despite an excellent prognosis even for patients with disseminated disease, about 20% to 30% of men with advanced germ cell tumors are refractory to first-line chemotherapy or experience disease recurrence after an initial remission with such treatment. Many of these are cured with conventional dose cisplatin/ifosfamide-based regimen or high-dose chemotherapy with stem cell rescue. Controversy exists regarding the optimal choice between these 2 second-line approaches, and available data for each...
